Loading...
Back to narrative

SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year

SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook

SHC logo
SHC
AnalystConsensusTarget
Not Invested
Published 02 Sep 2024

Update shared on 30 Nov 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
28.0%
7D
0.5%

Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios.

What's in the News

  • Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).
  • The company also filed a Follow-on Equity Offering amounting to $480.3 million, consisting of 30 million shares at a price range of $16.01 (Key Developments).
  • Several forms of Sotera Health Company's securities, including common stock, restricted stock units, and options, are subject to lock-up agreements that will end in October and December 2025. These agreements restrict certain transactions for periods ranging from 31 to 46 days, beginning in late 2025 (Key Developments).
  • Sotera Health reaffirmed its revenue guidance for the full year 2025, expecting net revenue growth between 4.5% and 6.0% on a constant currency basis (Key Developments).

Valuation Changes

  • Consensus Analyst Price Target remains unchanged at $18.93 per share.
  • The discount rate has fallen slightly, moving from 8.90% to 8.81%.
  • The revenue growth projection is essentially unchanged, staying at 6.23%.
  • Net profit margin forecasts remain steady at 27.55%.
  • The future P/E ratio has decreased marginally, from 18.40x to 18.30x.

Have other thoughts on Sotera Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.